These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8055985)

  • 1. Platyspondyly in treated beta-thalassemia.
    Orzincolo C; Castaldi G; Scutellari PN
    Eur J Radiol; 1994 May; 18(2):129-33. PubMed ID: 8055985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Platyspondylisis+ in beta-thalassemia major].
    Orzincolo C; Castaldi G; Scutellari PN; Scapoli A; Ghedini M
    Radiol Med; 1992 Dec; 84(6):731-5. PubMed ID: 1494673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients.
    Levin TL; Sheth S; Berdon WE; Ruzal-Shapiro C; Piomelli S
    Pediatr Radiol; 1995 Nov; 25 Suppl 1():S122-4. PubMed ID: 8577502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of skeletal dysplasia in thalassaemia major.
    Naselli A; Vignolo M; Di Battista E; Garzia P; Forni GL; Traverso T; Aicardi G
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():817-25. PubMed ID: 10091152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients.
    Hartkamp MJ; Babyn PS; Olivieri F
    Pediatr Radiol; 1993; 23(7):525-8. PubMed ID: 8309754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The evolutionary effects of therapy on the skeletal lesions in beta-thalassemia].
    Orzincolo C; Castaldi G; Bariani L; Scutellari PN
    Radiol Med; 1994 Apr; 87(4):381-8. PubMed ID: 8190918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferoxamine-induced bone dysplasia in patients with thalassemia major.
    Brill PW; Winchester P; Giardina PJ; Cunningham-Rundles S
    AJR Am J Roentgenol; 1991 Mar; 156(3):561-5. PubMed ID: 1899759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of thalassemia treated with conventional therapy.
    Borgna-Pignatti C; Zurlo MG; DeStefano P; Boffa C; DeSanctis V; DiPalma A; DiGregorio L; Melevendi C; Piga A; Sabato V
    Bone Marrow Transplant; 1993; 12 Suppl 1():2-4. PubMed ID: 8374554
    [No Abstract]   [Full Text] [Related]  

  • 10. [Measurement of the secretion of growth hormone in patients with thalassemia major].
    De Luca G; Maggiolini M; Bria M; Caracciolo M; Lanzino M; Le Pera M; Brancati C; Andò S
    Minerva Endocrinol; 1993 Sep; 18(3 Suppl 1):62-5. PubMed ID: 7910656
    [No Abstract]   [Full Text] [Related]  

  • 11. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anomalies of the masticatory apparatus in beta-thalassemia. The present status after transfusion and iron-chelating therapy].
    Scutellari PN; Orzincolo C; Andraghetti D; Gamberini MR
    Radiol Med; 1994 Apr; 87(4):389-96. PubMed ID: 8190919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short stature and body proportion in thalassaemia.
    Caruso-Nicoletti M; De Sanctis V; Capra M; Cardinale G; Cuccia L; Di Gregorio F; Filosa A; Galati MC; Lauriola A; Malizia R; Mangiagli A; Massolo F; Mastrangelo C; Meo A; Messina MF; Ponzi G; Raiola G; Ruggiero L; Tamborino G; Saviano A
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():811-6. PubMed ID: 10091151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal abnormalities in β-thalassemia major.
    Bhoiwala DL; Dunaief JL
    Surv Ophthalmol; 2016; 61(1):33-50. PubMed ID: 26325202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
    Ehlers KH; Giardina PJ; Lesser ML; Engle MA; Hilgartner MW
    J Pediatr; 1991 Apr; 118(4 Pt 1):540-5. PubMed ID: 2007928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
    Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac status in well-treated patients with thalassemia major.
    Aessopos A; Farmakis D; Hatziliami A; Fragodimitri C; Karabatsos F; Joussef J; Mitilineou E; Diamanti-Kandaraki E; Meletis J; Karagiorga M
    Eur J Haematol; 2004 Nov; 73(5):359-66. PubMed ID: 15458515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.
    Cazzola M; Borgna-Pignatti C; Locatelli F; Ponchio L; Beguin Y; De Stefano P
    Transfusion; 1997 Feb; 37(2):135-40. PubMed ID: 9051086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.
    Calleja EM; Shen JY; Lesser M; Grady RW; New MI; Giardina PJ
    Ann N Y Acad Sci; 1998 Jun; 850():469-70. PubMed ID: 9668587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.